170 related articles for article (PubMed ID: 15451564)
1. Differential actions of follistatin and follistatin-like 3.
Schneyer A; Sidis Y; Xia Y; Saito S; del Re E; Lin HY; Keutmann H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):25-8. PubMed ID: 15451564
[TBL] [Abstract][Full Text] [Related]
2. Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter.
Bartholin L; Guindon S; Martel S; Corbo L; Rimokh R
Gene; 2007 May; 393(1-2):153-62. PubMed ID: 17395406
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.
Xia Y; Sidis Y; Schneyer A
Mol Endocrinol; 2004 Apr; 18(4):979-94. PubMed ID: 14739256
[TBL] [Abstract][Full Text] [Related]
4. Heparin and activin-binding determinants in follistatin and FSTL3.
Sidis Y; Schneyer AL; Keutmann HT
Endocrinology; 2005 Jan; 146(1):130-6. PubMed ID: 15471966
[TBL] [Abstract][Full Text] [Related]
5. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
7. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3.
Saito S; Sidis Y; Mukherjee A; Xia Y; Schneyer A
Endocrinology; 2005 Dec; 146(12):5052-62. PubMed ID: 16150905
[TBL] [Abstract][Full Text] [Related]
8. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
Stamler R; Keutmann HT; Sidis Y; Kattamuri C; Schneyer A; Thompson TB
J Biol Chem; 2008 Nov; 283(47):32831-8. PubMed ID: 18768470
[TBL] [Abstract][Full Text] [Related]
9. Novel factors in regulation of activin signaling.
Tsuchida K; Nakatani M; Matsuzaki T; Yamakawa N; Liu Z; Bao Y; Arai KY; Murakami T; Takehara Y; Kurisaki A; Sugino H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):1-8. PubMed ID: 15451561
[TBL] [Abstract][Full Text] [Related]
10. FLRG, member of the follistatin family, a new player in hematopoiesis.
Maguer-Satta V; Rimokh R
Mol Cell Endocrinol; 2004 Oct; 225(1-2):109-18. PubMed ID: 15451575
[TBL] [Abstract][Full Text] [Related]
11. A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin.
Maguer-Satta V; Forissier S; Bartholin L; Martel S; Jeanpierre S; Bachelard E; Rimokh R
Exp Cell Res; 2006 Feb; 312(4):434-42. PubMed ID: 16336961
[TBL] [Abstract][Full Text] [Related]
12. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).
Schneyer A; Schoen A; Quigg A; Sidis Y
Endocrinology; 2003 May; 144(5):1671-4. PubMed ID: 12697670
[TBL] [Abstract][Full Text] [Related]
13. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin.
Gilson H; Schakman O; Kalista S; Lause P; Tsuchida K; Thissen JP
Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E157-64. PubMed ID: 19435857
[TBL] [Abstract][Full Text] [Related]
14. The role of follistatin domains in follistatin biological action.
Keutmann HT; Schneyer AL; Sidis Y
Mol Endocrinol; 2004 Jan; 18(1):228-40. PubMed ID: 14563935
[TBL] [Abstract][Full Text] [Related]
15. Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.
Brown ML; Bonomi L; Ungerleider N; Zina J; Kimura F; Mukherjee A; Sidis Y; Schneyer A
Obesity (Silver Spring); 2011 Oct; 19(10):1940-9. PubMed ID: 21546932
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 9 (GDF9) suppresses follistatin and follistatin-like 3 production in human granulosa-lutein cells.
Shi FT; Cheung AP; Huang HF; Leung PC
PLoS One; 2011; 6(8):e22866. PubMed ID: 21829661
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the existence of a local activin follistatin negative feedback loop in the goldfish pituitary and its regulation by activin and gonadal steroids.
Cheng GF; Yuen CW; Ge W
J Endocrinol; 2007 Dec; 195(3):373-84. PubMed ID: 18000300
[TBL] [Abstract][Full Text] [Related]
18. Follistatin-related protein (FSRP): a new member of the follistatin gene family.
Schneyer A; Tortoriello D; Sidis Y; Keutmann H; Matsuzaki T; Holmes W
Mol Cell Endocrinol; 2001 Jun; 180(1-2):33-8. PubMed ID: 11451569
[TBL] [Abstract][Full Text] [Related]
19. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.
Cash JN; Angerman EB; Keutmann HT; Thompson TB
Mol Endocrinol; 2012 Jul; 26(7):1167-78. PubMed ID: 22593183
[TBL] [Abstract][Full Text] [Related]
20. Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.
Oldknow KJ; Seebacher J; Goswami T; Villen J; Pitsillides AA; O'Shaughnessy PJ; Gygi SP; Schneyer AL; Mukherjee A
Endocrinology; 2013 Mar; 154(3):1310-20. PubMed ID: 23407452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
